A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency

Pediatric Transplantation

Volumn 18, Issue 6, 2014, Pages 609-616

  Dvorak, Christopher C ^a   Horn, Biljana N ^a   Puck, Jennifer M ^a   Adams, Stuart ^b   Veys, Paul ^b   Czechowicz, Agnieszka ^c   Cowan, Morton J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alemtuzumab; engraftment; haploidentical; severe combined immunodeficiency

Indexed keywords

ALEMTUZUMAB; DEXAMETHASONE; DIPHENHYDRAMINE; PARACETAMOL; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BRADYCARDIA; CASE REPORT; CHILD; ENGRAFTMENT; FEVER; FLOW CYTOMETRY; FOLLOW UP; HUMAN; INFANT; MALE; MONOTHERAPY; NATURAL KILLER CELL; PILOT STUDY; PROSPECTIVE STUDY; RIGOR; SEVERE COMBINED IMMUNODEFICIENCY; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERE COMBINED IMMUNODEFICIENCY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84906088228     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12310     Document Type: Article

References (44)

1. Dvorak C, Cowan M,. Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplant 2008: 41: 119-126.
2. Dvorak C, Hung G, Horn B, Dunn E, Oon C, Cowan M,. Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant 2008: 14: 1125-1133.
3. Murphy WJ, Kumar V, Bennett M,. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med 1987: 165: 1212-1217.
4. Hamby K, Trexler A, Pearson TC, Larsen CP, Rigby MR, Kean LS,. NK cells rapidly reject allogeneic bone marrow in the spleen through a perforin- and Ly49D-dependent, but NKG2D-independent mechanism. Am J Transplant 2007: 7: 1884-1896.
5. Xiao Z, Dunn E, Singh K, Khan I, Yannone S, Cowan M,. A non-leaky Artemis-deficient mouse that accurately models the human severe combined immune deficiency phenotype, including resistance to hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009: 15: 1-11.
6. Westerhuis G, Maas W, Willemze R, Toes R, Fibbe W,. Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. Blood 2005: 106: 2215-2220.
7. Cho S, Shuto Y, Soda Y, et al. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation. Exp Hematol 2004: 32: 1246-1254.
8. Robertson L, Denny A, Huh Y, Plunkett W, Keating M, Nelson J,. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol 1996: 37: 445-450.
9. Schuetz C, Neven B, Dvorak C, et al. SCID patients with ARTEMIS versus RAG deficiencies following HCT: Increased risk of late toxicity in ARTEMIS deficient SCID. Blood 2013: 123: 281-289.
10. Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after haematopoietic stem cell transplantation of a single-centre cohort of 90 patients with severe combined immunodeficiency: Long-term outcome of HSCT in SCID. Blood 2009: 113: 4114-4124.
11. Dvorak C, Cowan M,. Radiosensitive severe combined immunodeficiency disease. Immunol Allergy Clin North Am 2010: 30: 125-142.
12. Penack O, Fischer L, Stroux A, et al. Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation. Bone Marrow Transplant 2008: 41: 377-383.
13. Law J, Cowan M, Dvorak C, et al. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant 2012: 18: 1656-1663.
14. Straathof K, Rao K, Eyrich M, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: A phase 1/2 study. Lancet 2009: 374: 912-920.
15. Griffith L, Cowan M, Notarangelo L, et al. Improving cellular therapy for primary immune deficiency diseases: Recognition, diagnosis, and management. J Allergy Clin Immunol 2009: 124: 1152-1160.
16. Dvorak C, Cowan M, Logan B, et al. The natural history of children with severe combined immunodeficiency: Baseline features of the first fifty patients of the Primary Immune Deficiency Treatment Consortium prospective study 6901. J Clin Immunol 2013: 33: 1156-1164.
17. Ozyurek E, Cowan M, Koerper M, Baxter-Lowe L, Dvorak C, Horn B,. Outcomes of children with unstable mixed chimerism after reduced intensity hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant 2008: 42: 83-91.
18. Scharf S, Smith A, Hansen J, McFarland C, Erlich H,. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995: 85: 1954-1963.
19. Rebello P, Hale G,. Pharmacokinetics of CAMPATH-1H: Assay development and validation. J Immunol Methods 2002: 260: 285-305.
20. Comans-Bitter W, de Groot R, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997: 130: 388-393.
21. Huenecke S, Behl M, Fadler C, et al. Age-matched lymphocyte subpopulation reference values in childhood and adolescence: Application of exponential regression analysis. Eur J Haematol 2008: 80: 532-539.
22. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995: 15: 825-828.
23. Filipovich A, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005: 11: 945-956.
24. Puck J,. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: The winner is T-cell receptor excision circles. J Allergy Clin Immunol 2012: 129: 607-616.
25. Bakare N, Menschik D, Tiernan R, Hua W, Martin D,. Severe combined immunodeficiency (SCID) and rotavirus vaccination: Reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 2010: 28: 6609-6612.
26. Dvorak C, Gilman A, Horn B, et al. Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions. Bone Marrow Transplant 2009: 44: 805-812.
27. Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006: 135: 382-385.
28. Prasad V, Lucas K, Kleiner G, et al. Efficacy and safety of ex-vivo cultured adult human mesenchymal stem cells (Prochymal(TM)) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011: 17: 534-541.
29. Dror Y, Gallagher R, Wara DW, et al. Immune reconstitution in severe combined immunodeficiency disease after lectin-treated. T-cell-depleted haplocompatible bone marrow transplantation. Blood 1993: 81: 2021-2030.
30. Fischer A, Landais P, Friedrich W, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet 1990: 336: 850-854.
31. Styczynski J, Tallamy B, Waxman I, et al. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2010: 46: 790-799.
32. Bhatla D, Davies S, Shenoy S, et al. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant 2008: 42: 159-165.
33. Stauch D, Dernier A, Sarmiento Marchese E, et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: Similar effects independent of specificity. PLoS One 2009: 4: e4709.
34. Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005: 105: 879-885.
35. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G,. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001: 3: 261-267.
36. Riechmann R, Clark M, Waldmann H, Winter G,. Reshaping human antibodies for therapy. Nature 1988: 332: 323-327.
37. Klabusay M, Sukova V, Coupek P, Brychtova Y, Mayer J,. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. Cytometry B Clin Cytom 2007: 72: 363-370.
38. Morisot S, Georgantas R, Civin C,. Hematopoietic stem-progenitor cells express CD52 mRNA and membrane protein. Mol Ther 2006: 13: S131 (abstract).
39. Gentles A, Plevritis S, Majeti R, Alizadeh A,. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010: 304: 2706-2715.
40. Seita J, Sahoo D, Rossi D, et al. Gene expression commons: An open platform for absolute gene expression profiling. PLoS One 2012: 7: e40321.
41. Olweus J, Lund-Johansen F, Terstappen L,. Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells. Immunomethods 1994: 5: 179-188.
42. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998: 22: 185-191.
43. Logan A, Czechowicz A, Kelley B, et al. Anti-CD117 (c-Kit) monoclonal antibodies deplete human hematopoietic stem cells and facilitate their replacement in humanized NOD/SCID/IL2Rγ-/- mice: A non-toxic conditioning regimen for allotransplantation. Blood (ASH Annual Meeting Abstracts) 2012: 120: 4099.
44. Dickinson A, Reid M, Abinun M, et al. In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID). Bone Marrow Transplant 1997: 19: 323-329.